Insider Buying Persists as ProMIS Neurosciences Shares Dip Toward $3.43—Executives Signal Long‑Term Confidence in Neuro‑Therapeutic Pipeline
Insider buying at ProMIS Neurosciences shows confidence amid volatility—evidence of long‑term belief in a first‑in‑class neurotherapeutic.
3 minutes to read
